Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has approved two new treatments for generalized myasthenia gravis (gMG) within days of each other. Klygefa (gefurulimab), a first-of-its-kind dual-binding nanobody C5 inhibitor, offers once-weekly self-injection at home, while Livsayis (cemdisiran), the first siRNA therapy for gMG, requires only four doses per year. Both target the complement pathway and showed meaningful improvements in daily functioning in phase 3 trials.
The FDA has approved two new complement-targeting therapies for generalized myasthenia gravis (gMG) in rapid succession, significantly expanding the treatment landscape for a condition that causes debilitating, fluctuating muscle weakness in an estimated 98,500 Americans.
Klygefa (gefurulimab), approved November 16, 2026, is the first dual-binding nanobody complement C5 inhibitor. It blocks C5 in the terminal complement cascade while also binding serum albumin to extend its half-life — enabling once-weekly, self-administered subcutaneous dosing via autoinjector. The phase 3 PREVAIL trial (n=260) showed a statistically significant improvement in MG-ADL scores at week 26 (treatment difference: −1.6 points; P<.001), with benefits appearing as early as week 1. Livsayis (cemdisiran), approved November 18, 2026, takes a different approach: it's the first siRNA therapy for gMG, reducing hepatic C5 production rather than binding circulating C5 — and needs only four doses per year. The phase 3 NIMBLE trial showed a 2.3-point placebo-adjusted improvement in MG-ADL scores (P=.0005), with 76.6% of patients achieving a clinically meaningful response vs. 44.1% on placebo.
By the Numbers:
Why it matters: With these approvals, gMG now has four complement-targeted therapies, giving neurologists more flexibility to tailor treatment to patient lifestyle, dosing preferences, and disease profile. The addition of a quarterly siRNA option and a weekly at-home injector marks a meaningful shift toward more convenient, patient-empowering care for a historically difficult-to-manage condition.